Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.80 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 11/20 | 0.55 |
| ▸ | PPARA | Q07869 | 11/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893027 | 0.89 | KDM4E (1.00) | KDM4EHPGDPPARGPPARAFFAR1 | |
| SCHEMBL4936759 | 0.86 | KDM4E (0.78) | KDM4EHPGDPPARGPPARAFFAR1 | |
| SCHEMBL22549565 | 0.85 | KDM4E (0.59) | KDM4EPPARATP53LMNA | |
| SCHEMBL12883728 | 0.85 | KDM4E (0.76) | KDM4EHPGDPPARGPPARAFFAR1 | |
| SCHEMBL12868351 | 0.84 | KDM4E (0.74) | KDM4EHPGDPPARGPPARAFFAR1 | |
| SCHEMBL8573755 | 0.84 | KDM4E (0.74) | KDM4EHPGDPPARGPPARAFFAR1 | |
| SCHEMBL2930640 | 0.84 | KDM4E (0.74) | KDM4EHPGDPPARGPPARAFFAR1 | |
| SCHEMBL10165837 | 0.84 | KDM4E (0.74) | KDM4EHPGDPPARGPPARAFFAR1 | |
| SCHEMBL14260722 | 0.84 | KDM4E (0.74) | KDM4EHPGDPPARGPPARAFFAR1 | |
| SCHEMBL6437060 | 0.82 | KDM4E (0.72) | KDM4EHPGDPPARGPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | KDM4E 903/4885HPGD 1100/4885PPARG 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.